<DOC>
	<DOCNO>NCT00241605</DOCNO>
	<brief_summary>This 48-week study compare AVANDAMET vs. Metformin monotherapy blood glucose control patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients 18 75 year age Type 2 Diabetes Mellitus currently metformin monotherapy glycemic control ( 100mg daily least 3 month prior screen ) . Patients must stop previous treatment thiazolidinediones antidiabetic agent least 3 month prior screen . Women must postmenopausal , surgically sterile use acceptable contraceptive measure . Prior history hepatocellular reaction severe edema associate use thiazolidinediones . Have know hypersensitivity thiazolidinediones biguanides . Currently use insulin oral antidiabetic agent metformin . History metabolic acidosis . History substance abuse . Have active cancer localize squamous basal cell carcinoma . Chronic disease require treatment corticosteroid . Other criterion evaluate screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Metformin</keyword>
	<keyword>AVANDAMET</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>